Active Biotech AB (publ) announced that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer, effective January 1, 2022. He will join the executive management team and be responsible for the development of the company´s clinical project portfolio within solid and hematological cancers, and inflammatory eye disorders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4895 SEK | -2.10% | -1.71% | +7.23% |
22/05 | Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug | MT |
22/05 | Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology | CI |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.23% | 16.71M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- ACTI Stock
- News Active Biotech AB
- Active Biotech AB Appoints Erik Vahtola as Chief Medical Officer